6.30 0.00 (0.00%)
After hours: 5:46PM EDT
|Bid||6.27 x 1300|
|Ask||6.34 x 800|
|Day's Range||6.00 - 6.32|
|52 Week Range||5.00 - 26.79|
|Beta (3Y Monthly)||1.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Insider Monkey has processed numerous 13F filings of hedge funds and successful investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news […]
If you want to know who really controls Sientra, Inc. (NASDAQ:SIEN), then you'll have to look at the makeup of its...
Shares of Sientra Inc (NASDAQ: SIEN ) have declined about 25 percent since the company reported its first-quarter results on May 8. Meanwhile, the industry backdrop has improved and the near-term financing ...
The Santa Barbara, California-based company said it had a loss of 91 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Sientra, Inc. (NASDAQ:SIE...
The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants. Last month, the FDA issued a statement https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm630863.htm warning doctors about a type of lymphoma linked to breast implants after receiving reports of the disease. The agency's letters http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190319:nPn7rwbQSa, dated March 18, highlighted issues in the companies' post-approval studies, which included evaluating the long-term performance and safety of the implants, used for breast augmentation and reconstruction procedures.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
Stocks that moved substantially or traded heavily on Wednesday: Rite Aid Corp., up 4 cents to 72 cents The drugstore chain purged its top management, including CEO John Stanley, and said it will cut 400 ...
, a plastic surgery product maker, were falling hard Wednesday after the company reported a wider-than-expected fourth-quarter loss. Sientra lost 87 cents a share in the quarter, wider than analysts' calls for a loss of 67 cents. The company has missed earnings estimates in the last four quarters.
Sientra (SIEN) delivered earnings and revenue surprises of -28.36% and 0.83%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Santa Barbara, California-based company said it had a loss of 86 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors are always looking for growth inRead More...
“October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being ’08 and the Crash of ’87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
In 2015 Jeff Nugent was appointed CEO of Sientra, Inc. (NASDAQ:SIEN). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look Read More...